Solid Tumors

Treatment

MATCH Screening

If matches (a) mutation(s) in 1 ≤ treatment arms

ECOG-ACRIN-EAY131
Molecular Analysis for Therapy Choice (MATCH)
PI: Ford Pfizer

VAR0165
Phase II Anti-Tumor Activity of Avelumab in Combo w/ Talazoparib in BRCA or ATM Mutant Tumors
PI: Tehrani Seattle Genetics

BRCA 1/2 ATM

VAR0161
Open Label Phase 2 Study of Tisodium Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors
*Open at South Bay Cancer Center only
PI: Tehrani Seattle Genetics

HER2

VAR0160
Phase II Neratinib in Solid Tumors w/ Somatic Human EGFR/HER2/HER3 Mutations /EGFR GeneAmplification
PI: Ford Puma Biotechnology

VAR0118
Phase Ila Trastuzumab/ Pertuzumab Erlotinib Vemurafenib/ Cobimetinib &Vismodegib in Solid Tumors
PI: Ford Genentech

1st Priority
2nd Priority

KEY

Pending
Open for Enrollment
Optional Path
Trial Posting
Extension Study
Immunotherapy
Enrollment on Hold

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu